Nukkleus Inc. (NASDAQ:NUKK - Get Free Report) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 259,500 shares, a growth of 27.3% from the May 15th total of 203,800 shares. Based on an average daily trading volume, of 168,300 shares, the short-interest ratio is currently 1.5 days. Currently, 6.4% of the shares of the stock are short sold.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen raised shares of Nukkleus from a "sell" rating to a "hold" rating in a research note on Friday, May 30th.
Check Out Our Latest Analysis on NUKK
Institutional Investors Weigh In On Nukkleus
An institutional investor recently bought a new position in Nukkleus stock. Compagnie Lombard Odier SCmA acquired a new stake in shares of Nukkleus Inc. (NASDAQ:NUKK - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 6,200 shares of the company's stock, valued at approximately $74,000. Compagnie Lombard Odier SCmA owned approximately 0.13% of Nukkleus at the end of the most recent reporting period. 12.47% of the stock is owned by institutional investors and hedge funds.
Nukkleus Stock Down 12.0%
NUKK stock opened at $10.64 on Wednesday. Nukkleus has a 12 month low of $1.30 and a 12 month high of $78.32. The company has a 50-day moving average price of $14.86 and a 200 day moving average price of $17.49.
Nukkleus (NASDAQ:NUKK - Get Free Report) last released its quarterly earnings results on Friday, May 23rd. The company reported $18.19 EPS for the quarter.
Nukkleus Company Profile
(
Get Free Report)
Nukkleus Inc, a financial technology company, provides blockchain-enabled technology solutions worldwide. It focuses on providing software and technology solutions for retail foreign exchange trading industry. The company provides transactions platform for dealing and risk management services. It also offers cross-border payment and transactions solutions and blockchain-enabled financial services solutions to institutional investors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nukkleus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nukkleus wasn't on the list.
While Nukkleus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
